Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

HHS is pulling multiple levers to speed drug R&D. Last week, it launched a new program aimed at finding “groundbreaking” ideas to speed clinical trials. Called SURPASS, the program is being run by HHS ...

The FDA is continuing its push to expedite early-stage research for drug developers and is now accepting applications for a new pilot program aimed at accelerating U.S. clinical trials. The primary ...